News

OSIR

Osiris Therapeutics Inc (OSIR) Drops 7.3% on January 11

Equities Staff | Equities.com |

Osiris Therapeutics Inc (OSIR) was one of the Russell 2000's biggest losers for Monday January 11 as the stock slid 7.3% to $9.02, a loss of $-0.71 per share. Starting at an opening price of


Osiris Therapeutics Inc (OSIR) is Trading Lower on Unusual Volume for December 21

Equities Staff | Equities.com |

Osiris Therapeutics Inc (OSIR) experienced unusually high volume on Dec. 21, as the stock lost 6.38% to a closing price of $10.21. The stock saw 1.42 million shares trade hands over the course of


Osiris Therapeutics Inc (OSIR) Drops 6.38% on December 21

Equities Staff | Equities.com |

Osiris Therapeutics Inc (OSIR) was one of the Russell 2000's biggest losers for Monday December 21 as the stock slid 6.38% to $10.21, a loss of $-0.695 per share. Starting at an opening price


Why Japan is Crucial to the Future of Stem Cell Research

The Life Sciences Report | Equities.com |

Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this


Biotech Investors Need to Focus on Catalysts

The Life Sciences Report | Equities.com |

When progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestones—which act as catalysts—are met. The


Diabetes Treatments Lead Mannkind and Osiris Higher

Michael Teague | Equities.com |

On Tuesday, shares for biotech company Osiris Therapeutics (OSIR) vaulted over 125 percent within the first few hours of trading, closing the day on an advance of almost 140 percent to


Wall Street Breaks 3-Day Losing Streak As Tech Shares Advance

Michael Teague | Equities.com |

Stocks rose on Tuesday, sending all indices higher as Wall Street digested further confirmations that the Federal Reserve’s planned gradual drawdown of fiscal stimulus could become a reality


5 Micro and Small-Cap Biotechs Developing Stem Cell Treatments

Michael Teague | Equities.com |

Stem cells have once again flitted through the news cycle, this time as a result of a new and growing industry that has arisen around the use of adult stem cells in cosmetic treatments that


Stocks Under $10: More Hold-Rated Biomed/Genetics in the Medical Sector

Richard Suttmeier | Equities.com |

At www.ValuEngine.com we show that the Medical sector 12.1% overvalued with the Medical Biomed / Genetics 13.7% overvalued. All 17 stocks in today’s table have complete ValuEngine data and have


Equities Sector Coverage: Facebook's IPO Much Ado About Nothing?

Sector Recap | Equities.com |

The Facebook (FB) IPO, priced at $38 per share with a record market cap at $104 billion The IPO raised $18.4 billion for Facebook. The opening process began at 11:00 AM on the NASDAQ, with a


World Economic Forum at Davos 2019 - Ben Yablon Executive VP Salt Lending

Matt Bird sits down with Ben Yablon - Executive VP of Salt Lending - at the World Economic Forum in Davos January 2019